Combination Therapy with Metoprolol and Verapamil

Introduction to Combination Therapy Risks

• Metoprolol, a beta-blocker, antagonizes sympathetic tone in nodal tissue, further slowing conduction, which can lead to atrioventricular (AV) block when combined with verapamil, a non-dihydropyridine calcium channel blocker 1
• The combination of metoprolol and verapamil acts synergistically to depress AV node function, sinus node function, and myocardial contractility, increasing the risk of AV block and other serious cardiac adverse effects 2

Alternative Treatment Approaches

• For rate control in atrial fibrillation, the European Society of Cardiology recommends using metoprolol alone as first-line therapy 3
• For supraventricular tachycardia, the American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS) guidelines suggest considering other options 4

Patient Monitoring and Management

• Patients on combination therapy should be closely monitored, including continuous ECG monitoring during initiation, regular assessment of PR interval prolongation, blood pressure monitoring, and electrolyte monitoring, particularly potassium levels 2
• The American College of Cardiology recommends having resuscitation equipment readily available and considering calcium chloride as a rescue medication for patients on this combination 4